<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Lifestars Awards 2018 celebrate life science succe...

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

€79m Series C pushes Galecto Biotech’s pipeline in...

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More

Driving developments to defeat ageing: Q&A with Au...

In February 2019, key stakeholders in the growing longevity industry will c...

Read More

Artios Pharma’s £65m Series B to spur development ...

Key findings:

Read More

Dyadic International: Working to change the game i...

Key learnings:

Read More

What life sciences companies need to know about pr...

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Evox Therapeutics raises £35.5m Series B to advanc...

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More

Commercialise and partner successfully in Europe a...

Understand how to commercialise via partnering in Europe and other markets ...

Read More

Examining AI's potential in healthcare

Artificial Intelligence (AI) systems hold great potential in taking on an i...

Read More

Enhancing your drug development journey

Experience drug development – designed around you®

Read More

John Ratliff introduces the LSX C-Suite Challenges...

Heraclitus, the Greek philosopher, who said: “change is the only constant i...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More

Add Your Response